Quark Pharmaceuticals Announces Acceptance of Presentation and Abstracts at ASN 2018 (October 23-28, 2018) and AAO 2018 (October 27-30, 2018) Annual Meetings

October 22nd, 2018

Quark Pharmaceuticals, Inc Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

July 9th, 2018

Quark’s joint venture Riboquark announces the enrollment of the 1st ever Patient in China for a pivotal clinical trial with a siRNA drug candidate

November 13th, 2017

Quark Pharmaceuticals, Inc. to Present Positive Phase 2 Efficacy And Safety Results Of QPI-1002, A siRNA Targeting p53, For Prevention Of Acute Kidney Injury Following Cardiac Surgery, at the EuroTIDES Conference

November 7th, 2017

Quark Pharmaceuticals, Inc. Presents Results from a Positive Phase 2 Study of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery at the American Society of Nephrology Meeting

November 4th, 2017

Quark Pharmaceuticals, Inc. Phase 2 Data on the Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery to Be Presented at the American Society of Nephrology Meeting

November 1st, 2017

Quark Pharmaceuticals, Inc. to Present Preclinical Efficacy Data on Inhaled siRNA Co-Developed with Biocon for Prevention of Primary Graft Dysfunction following Lung Transplantation at the 6th Annual RNAi China Conference

October 9th, 2017

Quark Pharmaceuticals RNAi Drug Succeeds in Phase 2 Study to Prevent Acute Kidney Injury Following Cardiac Surgery

July 27th, 2017

Quark Pharmaceuticals Launches EyeActNow.com to Promote NAION Study Steps-Up Recruitment for Phase II/III Research on ‘Stroke of the Eye’

October 14th, 2016

Quark Pharmaceuticals Chief Scientist Provides an Overview of the Company’s Clinical and Nonclinical Pipelines

September 19th, 2016

Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant

July 28th, 2016

Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India

June 23rd, 2016

Quark Pharmaceuticals to Present Keynote Address at IBC’s 18th Annual TIDES Oligonucleotide and Peptide Therapeutics Conference

May 9th, 2016

Transplant Genomics® and Quark Pharmaceuticals Announce Discovery and Development Collaboration

April 14th, 2016

Quark Pharmaceuticals Doses First Patients in Two Pivotal Phase III Studies and One Phase II Study of RNAi-Based Therapeutics for Kidney and Eye Indications

March 14th, 2016

Quark announces issue of U.S. patent for novel treatment of lung transplantation associated injury

December 9th, 2015

Quark Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION

October 27th, 2015

Quark announces patent approval for Methods for treating eye disorders

September 1st, 2015

Quark will present at Eurotides 2015, Maritim proArte Hotel, Berlin, Germany ,16-18 Nov 2015

August 23rd, 2015

Quark announces patent approval for Compositions and methods for treatment of ear disorders

July 28th, 2015

Quark announces patent approval for therapeutic uses of inhibitors of RTP801

June 16th, 2015

Quark announces patent approval for double stranded RNA compounds to RhoA and use thereof

June 2nd, 2015

Quark announces patent approval for oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases

April 14th, 2015

Quark will present at 2015 American Transplant Congress, May 5, 2015

April 5th, 2015

Quark will present at TIDES 2015, at the Town and Country Hotel in San Diego, CA, May 3-6, 2015

April 3rd, 2015

Quark will present at The 7th GTC Ocular Disease Drug Discovery Conference. San Diego, CA. March 18-19, 2015.

February 18th, 2015

Quark announces patent approval for Methods for delivery of siRNA to the spinal cord and therapies arising therefrom

December 2nd, 2014

Quark announces Patent Approval for Oligonucleotide compounds comprising non-nucleotide overhangs

October 14th, 2014

Quark will present at Targeting Ocular Disorders. Boston, MA. October 6-7, 2014

September 6th, 2014

Quark announces patent approval for Sirna compounds comprising terminal substitutions

August 5th, 2014

Quark Pharmaceuticals Reports Favorable Results from Phase II Clinical Trial Evaluating Investigational siRNA QPI-1002

July 28th, 2014

Quark will present at 2014 World Transplant Congress July 26-31st 2014

July 26th, 2014

Quark Announces Completion of Phase II Trial Evaluating QPI-1002 for Prevention of Delayed Graft Function in Kidney Transplant Patients

July 1st, 2014

Quark Announces First Patient Dosed in a Phase IIa Trial Evaluating QPI-1007 for Neuroprotection in Patients with Acute Primary Angle Closure Glaucoma

June 25th, 2014

Quark will present at TIDES: Oligonucleotide Therapeutics Discovery. Providence, RI, May 12-15, 2014.

April 12th, 2014

Quark Pharmaceuticals and Suzhou Ribo Life Science Raise Nearly RMB 45 Million for Newly Established Chinese Joint Venture

January 7th, 2014

Biocon and Quark Pharmaceuticals Collaborate to Develop Novel siRNA based Therapeutics

December 18th, 2013

Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007

January 4th, 2012

In a Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months

March 18th, 2011

Rutgers Offers Hope in New Treatment for Spinal Cord Injuries

March 3rd, 2011

Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007

October 20th, 2010

Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human

August 18th, 2010

Nitto Denko and Quark Pharmaceuticals to Enter into Collaboration to Develop a Novel siRNA Anti-fibrotic Drug

July 15th, 2010

Quark Pharmaceutical’s QPI-1007 Exhibits Neuroprotective Effects in Glaucoma Model

June 28th, 2010

Quark Pharmaceuticals Announces Presentations of its Two siRNA Drug Candidates at Glaucoma & Retinopathies 2010

June 24th, 2010

Quark Granted European Orphan Drug Status for QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients

June 15th, 2010

Quark Pharmaceuticals Closes $10 Million Financing SBI Holdings, Inc. CEO Yoshitaka Kitao Appointed to Board. Funds to Support Advancing Clinical Pipeline

June 10th, 2010

Quark Pharmaceuticals Announces Nature Medicine Publication for Role of RTP801 in Pulmonary Injury and Emphysema

May 17th, 2010

Quark Pharmaceuticals Development Partner Pfizer Presents In Vivo Activity of PF-04523655 at ARVO

May 6th, 2010

Quark to Present Data on Predicting Risk of Delayed Graft Function in Kidney Transplant Patients at American Transplant Congress

May 4th, 2010

Quark Pharmaceuticals to Present Phase I Data for QPI-1002 in Delayed Graft Function at American Transplant Congress

May 4th, 2010

Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007

March 1st, 2010

FDA Grants Orphan Drug Status for Quark’s QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients

February 16th, 2010

Quark Pharmaceuticals Poised to Advance Clinical Studies of QPI-1002

January 5th, 2010

Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials

November 19th, 2009

Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases

November 2nd, 2009

Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene

October 26th, 2009

Quark Pharmaceuticals to Participate in IBC’s Oligonucleotide Therapeutics: From Concept to Implementation Conference

August 3rd, 2009

Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma

July 27th, 2009

Quark Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit

June 9th, 2009

Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage

May 14th, 2009

Pfizer and Quark

May 11th, 2009

Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3

May 11th, 2009

Quark Pharmaceuticals Presents at American Society for Pharmacology and Experimental Therapeutics Annual Meeting

April 20th, 2009

Quark Pharmaceuticals Presents at Asia TIDES Conference

March 9th, 2009

Quark Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function

January 9th, 2009

Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference

December 1st, 2008

Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy

October 13th, 2008

Quark Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property

September 25th, 2008

Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008

September 17th, 2008

Quark Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in DME

July 30th, 2008

Quark Pharmaceuticals Receives FDA Approval of IND For Kidney Transplant siRNA Drug DGFi

June 25th, 2008

Quark Closes $27 Million Financing

April 7th, 2008

Quark to Present at JPMorgan 26th Annual Healthcare Conference

December 20th, 2007

Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans

November 19th, 2007

Quark Pharmaceuticals, Inc. to Receive Development Milestone Payment from Mitsubishi Pharma Corporation

October 9th, 2007

Quark to Present at CIBC and Acumen BioFin Rodman & Renshaw

October 9th, 2007

Quark Pharmaceuticals Signs Collaboration Agreement with University of Michigan for Development of Proprietary siRNA Compounds for Noise-Induced Hearing Loss

September 24th, 2007

Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications To Its RNAi Molecules 

August 27th, 2007

Agreement with University of NY

August 20th, 2007

Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)

August 2nd, 2007

Silence Therapeutics And Quark Pharmaceuticals Expand Strategic Licensing Agreement

July 31st, 2007

COPD

June 16th, 2005

801 and Diabetes

April 28th, 2005

US Patent on P53 Inhibitor

March 3rd, 2005

Role of Ero-1L alpha Gene in Cancer

February 28th, 2005

Sanwa and Quark

February 8th, 2005